# Implementation Roadmap: Cross-Species EEI Analysis

## Executive Summary

Your current analysis provides a solid foundation for cross-species EEI analysis, but several key improvements are needed to achieve the goal of validating human cancer prognostic EEIs in mouse models. The main issues are: (1) lack of humanâ†’mouse ortholog mapping, (2) small sample size, and (3) simplified EEI definitions.

## Phase 1: Immediate Improvements (1-2 weeks)

### 1.1 Obtain Human CRPE Data
```python
# Download supplementary data from the paper
# URL: https://doi.org/10.5281/zenodo.12917451 (from paper)

def download_human_crpes():
    """Download the 3,316 human cancer-relevant perturbed EEIs"""
    # Download from paper's zenodo repository
    # Expected files:
    # - NETHIGH_CRPEs.txt (3,316 EEIs)
    # - NETMEDIUM_CRPEs.txt (9,224 EEIs) 
    # - NETLOW_CRPEs.txt (13,030 EEIs)
    
    human_crpes = pd.read_csv("NETHIGH_CRPEs.txt", sep='\t')
    return human_crpes
```

### 1.2 Implement Basic Ortholog Mapping
```python
def map_human_to_mouse_orthologs(human_crpes):
    """
    Basic ortholog mapping using biomart or pre-computed mappings
    """
    # Option 1: Use biomaRt (if available)
    # Option 2: Use HGNCâ†’MGI mapping files
    # Option 3: Use EGIO results if available
    
    # For now, use simple gene symbol mapping
    ortholog_mapping = pd.read_csv("human_mouse_orthologs.txt", sep='\t')
    # Columns: human_gene, mouse_gene, human_exon, mouse_exon
    
    return ortholog_mapping
```

### 1.3 Focused EEI Testing
```python
def test_orthologous_eeis_only(human_crpes, mouse_expression, ortholog_mapping):
    """
    Test only mouse EEIs that are orthologs of human CRPEs
    """
    # Map human CRPEs to mouse orthologs
    orthologous_eeis = map_crpes_to_mouse(human_crpes, ortholog_mapping)
    
    # Test only these specific EEIs
    results = test_eei_associations(orthologous_eeis, mouse_expression, survival_df)
    
    return results
```

## Phase 2: Enhanced Analysis (2-3 weeks)

### 2.1 Implement EGIO Pipeline
```bash
# Clone and setup EGIO
git clone https://github.com/username/EGIO-pipeline  # Update with actual repo
cd EGIO-pipeline

# Run humanâ†’mouse ortholog mapping
python egio_main.py \
  --species1 human \
  --species2 mouse \
  --gtf1 Homo_sapiens.GRCh38.gtf \
  --gtf2 Mus_musculus.GRCm39.gtf \
  --output human_mouse_orthologs
```

### 2.2 Structural Constraint Integration
```python
def add_structural_constraints(eei_list, pdb_contacts):
    """
    Filter EEIs based on protein structure contacts
    """
    # Load PDB contact data (from paper's methods)
    structural_contacts = load_pdb_contacts()
    
    # Filter EEIs to only those with structural evidence
    validated_eeis = []
    for eei in eei_list:
        if has_structural_contact(eei, structural_contacts):
            validated_eeis.append(eei)
    
    return validated_eeis
```

### 2.3 Improved EEI Definition
```python
def define_eei_presence_with_contacts(expression_df, eei_list, contact_data):
    """
    Define EEI presence using structural and expression constraints
    """
    # Use paper's method: CPM > 0.5 for expression
    # Add structural contact requirement
    
    for eei in eei_list:
        exon1, exon2 = eei['exon1'], eei['exon2']
        
        # Expression threshold (like paper)
        expr1_present = expression_df.loc[exon1] > 0.5  # CPM
        expr2_present = expression_df.loc[exon2] > 0.5
        
        # Structural contact (like paper)
        has_contact = check_structural_contact(exon1, exon2, contact_data)
        
        # EEI present = both expressed AND structural contact
        eei_present = expr1_present & expr2_present & has_contact
    
    return eei_presence_matrix
```

## Phase 3: Scale-Up and Validation (3-4 weeks)

### 3.1 Additional Mouse Datasets
```python
# Identify additional mouse cancer datasets
additional_datasets = [
    "GSE123456",  # Mouse breast cancer
    "GSE789012",  # Mouse liver cancer  
    "GSE345678",  # Mouse kidney cancer
]

def meta_analysis_across_datasets(dataset_list):
    """
    Run EEI analysis across multiple mouse cancer datasets
    """
    all_results = []
    
    for dataset in dataset_list:
        # Download and process each dataset
        expression, survival = download_and_process_geo(dataset)
        
        # Run EEI analysis
        results = test_orthologous_eeis(expression, survival)
        results['dataset'] = dataset
        all_results.append(results)
    
    # Meta-analysis
    meta_results = combine_results_across_datasets(all_results)
    return meta_results
```

### 3.2 Pathway-Level Analysis
```python
def pathway_enrichment_analysis(significant_eeis):
    """
    Test for pathway-level conservation
    """
    # Map EEIs to KEGG pathways (like paper)
    eei_pathways = map_eeis_to_pathways(significant_eeis)
    
    # Test for pathway enrichment
    enriched_pathways = test_pathway_enrichment(eei_pathways)
    
    return enriched_pathways
```

### 3.3 Cross-Validation Framework
```python
def cross_validate_eei_associations(expression_df, survival_df, n_folds=5):
    """
    Cross-validation to assess robustness
    """
    from sklearn.model_selection import KFold
    
    kf = KFold(n_splits=n_folds, shuffle=True, random_state=42)
    cv_results = []
    
    for train_idx, test_idx in kf.split(expression_df.columns):
        # Split samples
        train_expr = expression_df.iloc[:, train_idx]
        test_expr = expression_df.iloc[:, test_idx]
        
        # Train on training set
        eei_model = fit_eei_associations(train_expr, survival_df)
        
        # Test on test set  
        test_results = predict_eei_associations(eei_model, test_expr)
        cv_results.append(test_results)
    
    return cv_results
```

## Phase 4: Comprehensive Reporting (1 week)

### 4.1 Statistical Power Analysis
```python
def power_analysis_report():
    """
    Comprehensive power analysis for different scenarios
    """
    scenarios = [
        {'n_samples': 23, 'effect_size': 0.3, 'description': 'Current study'},
        {'n_samples': 50, 'effect_size': 0.3, 'description': 'With additional dataset'},
        {'n_samples': 100, 'effect_size': 0.3, 'description': 'Meta-analysis'},
        {'n_samples': 23, 'effect_size': 0.5, 'description': 'Larger effect size'},
    ]
    
    for scenario in scenarios:
        power = calculate_statistical_power(**scenario)
        print(f"{scenario['description']}: Power = {power:.2f}")
```

### 4.2 Comparative Analysis
```python
def compare_with_original_paper():
    """
    Compare mouse results with original human findings
    """
    # Load original paper results
    human_results = load_human_crpe_results()
    mouse_results = load_mouse_analysis_results()
    
    # Compare conservation rates
    conservation_rate = calculate_conservation_rate(human_results, mouse_results)
    
    # Pathway-level comparison
    pathway_conservation = compare_pathway_enrichment(human_results, mouse_results)
    
    return conservation_rate, pathway_conservation
```

## Expected Timeline and Milestones

### Week 1-2: Foundation
- âœ… Download human CRPE data
- âœ… Implement basic ortholog mapping  
- âœ… Focus analysis on orthologous EEIs
- ðŸŽ¯ **Milestone**: First ortholog-focused results

### Week 3-4: Enhancement  
- âœ… Setup EGIO pipeline
- âœ… Add structural constraints
- âœ… Improve EEI definitions
- ðŸŽ¯ **Milestone**: Structurally-informed EEI analysis

### Week 5-6: Scale-up
- âœ… Add 2-3 additional mouse datasets
- âœ… Implement meta-analysis
- âœ… Pathway-level analysis
- ðŸŽ¯ **Milestone**: Multi-dataset validation

### Week 7: Validation & Reporting
- âœ… Cross-validation analysis
- âœ… Power analysis report  
- âœ… Comparative analysis with human data
- ðŸŽ¯ **Milestone**: Complete analysis report

## Success Metrics

### Primary Outcomes
1. **Conservation Rate**: % of human CRPEs with significant mouse orthologs
2. **Effect Size**: Magnitude of associations in mouse vs human
3. **Pathway Conservation**: % of enriched pathways shared between species

### Secondary Outcomes  
1. **Statistical Power**: Achieved power for detecting associations
2. **Reproducibility**: Consistency across datasets and CV folds
3. **Biological Relevance**: Overlap with known cancer pathways

## Resource Requirements

### Computational
- **Storage**: ~50GB for additional datasets
- **Memory**: 16GB+ for large expression matrices
- **Time**: ~2-3 days compute time for full pipeline

### Data Sources
- **Human CRPEs**: Paper supplementary data
- **Mouse datasets**: GEO database  
- **Ortholog mappings**: EGIO pipeline or biomaRt
- **Structural data**: PDB complex structures

### Software Dependencies
```bash
# Python packages
pip install pandas numpy scipy statsmodels matplotlib seaborn

# R packages (for biomaRt)
R -e "BiocManager::install(c('biomaRt', 'GenomicFeatures'))"

# EGIO pipeline
git clone https://github.com/CoSBiLab/EGIO
cd EGIO
pip install -r requirements.txt
```

## Risk Mitigation

### Technical Risks
1. **EGIO Pipeline Issues**
   - *Risk*: EGIO may not work with current data formats
   - *Mitigation*: Have backup ortholog mapping using biomaRt/HGNC
   - *Contingency*: Use pre-computed ortholog databases

2. **Sample Size Limitations**
   - *Risk*: Even with additional datasets, power may remain low
   - *Mitigation*: Focus on pathway-level analysis which requires fewer samples
   - *Contingency*: Collaborate with other research groups for data sharing

3. **Cross-Species Differences**
   - *Risk*: Mouse biology may be too different from human
   - *Mitigation*: Focus on highly conserved pathways and processes
   - *Contingency*: Analyze tissue-specific patterns separately

### Data Quality Risks
1. **Expression Data Batch Effects**
   - *Risk*: Different datasets may have technical artifacts
   - *Mitigation*: Apply batch correction methods (ComBat, etc.)
   - *Contingency*: Analyze datasets separately and meta-analyze

2. **Annotation Inconsistencies**
   - *Risk*: Different Ensembl versions across datasets
   - *Mitigation*: Standardize all annotations to same genome build
   - *Contingency*: Use gene symbols as backup mapping strategy

## Quality Control Checkpoints

### Phase 1 QC
- [ ] Human CRPE data loaded correctly (3,316 EEIs)
- [ ] Ortholog mapping covers >80% of human genes
- [ ] Mouse EEI network filtered to orthologous pairs only
- [ ] Sample sizes adequate for basic testing (Nâ‰¥10 per group)

### Phase 2 QC  
- [ ] EGIO pipeline produces high-quality ortholog mappings
- [ ] Structural constraints reduce EEI list appropriately
- [ ] EEI definitions match original paper methodology
- [ ] Statistical tests show appropriate p-value distributions

### Phase 3 QC
- [ ] Additional datasets process without errors
- [ ] Meta-analysis results are consistent across datasets
- [ ] Pathway enrichment shows biological relevance
- [ ] Cross-validation demonstrates robustness

### Phase 4 QC
- [ ] Power analysis confirms adequate statistical power
- [ ] Results reproducible with different random seeds
- [ ] Comparative analysis shows meaningful conservation patterns
- [ ] All code documented and version controlled

## Communication Strategy

### Internal Updates
- **Weekly**: Progress reports with key metrics
- **Bi-weekly**: Technical deep-dives on specific challenges
- **Monthly**: Overall project status and timeline adjustments

### External Validation
- **Month 1**: Share preliminary results with collaborators
- **Month 2**: Present at lab meetings for feedback
- **Month 3**: Submit to relevant conferences/workshops

## Expected Results and Interpretation

### Scenario 1: Strong Conservation (Best Case)
- **Expectation**: 20-30% of human CRPEs show significant associations in mouse
- **Interpretation**: Cross-species conservation of EEI-cancer associations
- **Next Steps**: Experimental validation of top conserved EEIs

### Scenario 2: Moderate Conservation (Realistic)
- **Expectation**: 5-15% individual EEI conservation, stronger pathway-level conservation
- **Interpretation**: General mechanisms conserved, specific EEIs may be species-specific
- **Next Steps**: Focus on pathway-level therapeutic targets

### Scenario 3: Weak Conservation (Challenging)
- **Expectation**: <5% individual conservation, some pathway overlap
- **Interpretation**: Species differences significant, but some core pathways conserved
- **Next Steps**: Investigate tissue-specific or cancer-type-specific patterns

### Scenario 4: No Conservation (Worst Case)
- **Expectation**: No significant conservation at EEI or pathway level
- **Interpretation**: Major methodological issues or true biological divergence
- **Next Steps**: Revisit methodology, consider different mouse models

## Post-Analysis Opportunities

### Publication Opportunities
1. **Methods Paper**: "Cross-Species Analysis of Exon-Exon Interactions in Cancer"
2. **Validation Study**: "Conservation of Cancer Prognostic EEIs Across Species"
3. **Tool Development**: "Computational Pipeline for Cross-Species EEI Analysis"

### Follow-up Research
1. **Experimental Validation**: Test top conserved EEIs in cell culture
2. **Drug Target Discovery**: Screen compounds targeting conserved EEI interfaces
3. **Pan-Cancer Analysis**: Extend to multiple cancer types simultaneously

### Collaboration Opportunities
1. **Structural Biology**: Partner with groups doing protein complex crystallography
2. **Cancer Biology**: Collaborate with mouse cancer model experts
3. **Bioinformatics**: Share tools with other computational groups

## Code Organization and Version Control

### Repository Structure
```
cross_species_eei_analysis/
â”œâ”€â”€ data/
â”‚   â”œâ”€â”€ raw/              # Original downloaded data
â”‚   â”œâ”€â”€ processed/        # Cleaned and formatted data
â”‚   â””â”€â”€ results/          # Analysis outputs
â”œâ”€â”€ scripts/
â”‚   â”œâ”€â”€ 01_data_download.py
â”‚   â”œâ”€â”€ 02_ortholog_mapping.py
â”‚   â”œâ”€â”€ 03_eei_analysis.py
â”‚   â”œâ”€â”€ 04_visualization.py
â”‚   â””â”€â”€ 05_meta_analysis.py
â”œâ”€â”€ notebooks/
â”‚   â”œâ”€â”€ exploratory_analysis.ipynb
â”‚   â”œâ”€â”€ quality_control.ipynb
â”‚   â””â”€â”€ results_visualization.ipynb
â”œâ”€â”€ docs/
â”‚   â”œâ”€â”€ README.md
â”‚   â”œâ”€â”€ methods.md
â”‚   â””â”€â”€ results_summary.md
â”œâ”€â”€ tests/
â”‚   â””â”€â”€ test_analysis_functions.py
â”œâ”€â”€ environment.yml        # Conda environment
â”œâ”€â”€ requirements.txt      # Python packages
â””â”€â”€ config.yaml          # Analysis parameters
```

### Version Control Best Practices
```bash
# Initialize repository
git init
git add .
git commit -m "Initial commit: Cross-species EEI analysis pipeline"

# Create development branch
git checkout -b development

# Regular commits with descriptive messages
git commit -m "Add EGIO ortholog mapping functionality"
git commit -m "Implement structural constraint filtering"
git commit -m "Add meta-analysis across datasets"

# Tag major milestones
git tag -a v1.0-ortholog-mapping -m "Completed ortholog mapping phase"
git tag -a v2.0-structural-constraints -m "Added structural constraints"
```

## Final Recommendations

### Immediate Priority (This Week)
1. **Download human CRPE data** from the paper's supplementary materials
2. **Implement basic ortholog mapping** using available tools
3. **Re-run analysis focusing only on orthologous EEIs**

### Short-term Goals (Next Month)
1. **Set up EGIO pipeline** for high-quality ortholog mapping
2. **Add structural constraints** to match paper methodology
3. **Include 2-3 additional mouse cancer datasets**

### Long-term Vision (3-6 Months)
1. **Comprehensive cross-species validation** of cancer EEIs
2. **Pathway-level conservation analysis** 
3. **Publication of methodology and results**

The current analysis provides an excellent foundation. With these improvements, you should be able to achieve the goal of validating human cancer prognostic EEIs in mouse models and potentially discover novel conserved biomarkers for cross-species cancer research.